Core Viewpoint - 华领医药-B (02552) has shown significant growth in its mid-term performance, indicating successful commercialization and operational efficiency improvements [1] Financial Performance - For the six months ending June 30, 2025, the sales volume of 华堂宁® reached 1.764 million boxes, representing a year-on-year increase of 108% [1] - Net sales amounted to 217.4 million yuan, up 112% year-on-year [1] - The company achieved a profit of 1.1839 billion yuan in the first half of the year, marking its first profitable period [1] Commercialization and Operational Efficiency - Since taking over the commercialization of 华堂宁® in January 2025, the company has seen significant growth driven by its own sales team [1] - The expansion of medical insurance coverage has led to a substantial increase in prescriptions from secondary and tertiary hospitals [1] - The gross profit margin improved to 54.2%, an increase of 7.7 percentage points compared to the same period last year, indicating a positive trend in profitability [1] Strategic Developments - Following the termination of the exclusive promotion service agreement with Bayer, the company confirmed a one-time deferred income of 1.2435 billion yuan [1]
港股异动 | 华领医药-B(02552)涨超5% 上半年首次实现盈利 华堂宁销售表现强劲